To ask the Secretary of State for Health what assessment his Department has made of the draft guidance published by the National Institute for Health and Clinical Excellence proposing to refuse approval of the use of abiraterone for patients in England and Wales, and of the effect any such refusal might have on men with advanced prostate cancer and their families;
To ask the Secretary of State for Health what representations he has received on the use of cancer drugs for the treatment of advanced prostate cancer in advance of the National Institute for Health and Clinical Excellence guidance on the issue.
The National Institute for Health and Clinical Excellence (NICE) is currently appraising abiraterone (Zytiga) for two separate indications. NICE is an independent body and has not yet issued final guidance to the national health service on either indication.
The Department, as a registered stakeholder, has responded to NICE'S consultation on its draft guidance on the use of abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
We have received a number of representations from hon. Members, members of the public and industry with regard to this appraisal.